All News
Monoclonal antibodies have proven to be an important therapeutic option in the ongoing battle against COVID-19.
Avrobio’s ex vivo lentiviral gene therapy platform led to durable responses measured in years, and significant reductions in disease-related biomarkers that far exceed today’s standard of care.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones including T helper cells for COVID-19, new gene found that could contribute to type 1 diabetes and more.
Gilead Sciences announced it exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat.
Two weeks after Novartis announced it would sell its nearly one-third voting stake in next-door neighbor Roche, investors are chomping at the bit to find out how that almost $21 billion will be put to work.
Based on BridgeBio’s current pipeline of programs, this total amount will be sufficient to carry over 30 drug development and discovery programs well into 2024.
Merck’s Keytruda (pembrolizumab) keeps expanding the indications for which it’s approved. The company announced today that the FDA had approved the anti-PD-1 therapy for adjuvant treatment of renal cell carcinoma.
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
The Richard King Mellon Foundation has awarded a $100 million gift to the University of Pittsburgh and approved a $150 million grant for Carnegie Mellon University.
The FDA and CDC will soon decide on Pfizer-BioNTech’s request for an Emergency Use Authorization for the booster shot for their COVID-19 vaccine.
Novo Nordisk and Dicerna are no strangers. The companies have been collaborating on the development of RNAi therapies for liver disease for the past three years.
Generate Biomedicines, a machine-learning protein-therapy company, raked in $370 million in a Series B financing round that will be used to advance the company’s developmental programs.
The strategic collaboration entails a $180 million equity investment into Owkin and a total payment of $90 million over the next three years, in addition to milestone-based fees to be determined later.
Finding a job in the pharmaceutical industry can be challenging. Find out which skills can help you score your dream pharmaceutical company job.
The U.S. Securities and Exchange Commission has launched an investigation into Texas-based Cassava Sciences.
Seasonal Affective Disorder more than winter blues, and there are steps to take to prevent it or combat the sadness and lack of energy. Know more about it here.
Her career as a physician and scientist is guided by a combination of logic and creativity.
Biopharma and life sciences companies from across the globe provide updates. Belgium-based Galapagos NV won European approval for Jyseleca for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
Under the terms of their merger agreement, the deal can be terminated at any time. Know what happened between Valo Health & Khosla Ventures before the merger.
The decision comes after the Phase II MOONSONG trial on the oral antiviral pill AT-527 failed to meet the primary endpoint in October.